A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

Inclusion Criteria: * Males or females aged 18 to 55 years old (inclusive) at the time of signing the informed consent form. * Standard contraception measures are required for this clinical trial. * Healthy, in the opinion of the Investigator, based on prior (history of) or current (ongoing) medical and psychiatric screening assessments. * Participants with no clinically significant findings on physical examination, laboratory tests, and cardiac assessment. * Body mass index (BMI) within the range 18-32 kg/m2, inclusive. * Normal blood pressure. * Willing to not operate heavy machinery, including driving a vehicle at least 36 hours post Day 1 dose administration and 24 hours post all other dose administrations. * Capable of giving signed informed consent which includes the requirements and restrictions as per the approved study protocol Exclusion Criteria: * Prior known exposure to psilocybin, LSD, ayahuasca, N, N-Dimethyltryptamine, and related tryptamines, within the past 5 years. * Prior (history of) or current (ongoing) diagnosis, or first-degree relatives with clinically significant medical or psychiatric condition or disease. * History of non-hospitalized but medicated Major Depressive Disorder (MDD), Generalized Anxiety Disorder or Panic Disorder ≤ 5 years prior to Screening. * History of or presence of cardiovascular disease. * Abnormal and clinically significant ECG. * Known personal or family history of congenital long QT syndrome or sudden death. * Current or a …